ArticleNature communications2024
Single-cell transcriptional profile of CD34+ hematopoietic progenitor cells from del(5q) myelodysplastic syndromes and impact of lenalidomide.
Abstract read
In one paragraph
Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Article
- Myelodysplastic syndromes: Updates on Genomic Landscape, Molecular Subtypes, & Targeted Therapies.Current hematologic malignancy reports · 2025Review
- GeneSetCluster 2.0: a comprehensive toolset for summarizing and integrating gene-sets analysis.BMC bioinformatics · 2025Article
- Genotype-integrated single-cell transcriptome analysis reveals the role of DDX41 pR525H in a patient with myelodysplastic neoplasms.Scientific reports · 2025Article
- A reference model of circulating hematopoietic stem cells across the lifespan with applications to diagnostics.Nature medicine · 2025Article
- Natural killer cells' functional impairment drives the immune escape of pre-malignant clones in early-stage myelodysplastic syndromes.Nature communications · 2025Article
- The Emerging Role of CD8Cancers · 2025Review
- Targeting PD-L1 for PCNS-DLBCL: from molecular effects to clinical translation.Frontiers in immunology · 2025Review
- Long-term Sustained Response to Lenalidomide after Clearance of Bone Marrow Blasts by Azacytidine in High-risk Myelodysplastic Syndromes with Del5q: A Case Report.Cardiovascular & hematological agents in medicinal chemistry · 2025Article
- Single-cell transcriptional profile of CD34+ hematopoietic progenitor cells from del(5q) myelodysplastic syndromes and impact of lenalidomide.Nature communications · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors.
Guillermo Serrano *Computational Biology Program CIMA-Universidad de Navarra, Cancer Center Clínica Universidad de Navarra (CCUN), IdISNA, Pamplona, Spain.ORCID http://orcid.org/0000-0003-3972-6186
Nerea Berastegui *Hematology-Oncology Program, CIMA, Cancer Center Clínica Universidad de Navarra (CCUN), IdiSNA, Pamplona, Spain.ORCID http://orcid.org/0000-0002-9868-0547
Aintzane Díaz-Mazkiaran *Computational Biology Program CIMA-Universidad de Navarra, Cancer Center Clínica Universidad de Navarra (CCUN), IdISNA, Pamplona, Spain.
Paula García-OlloquiHematology-Oncology Program, CIMA, Cancer Center Clínica Universidad de Navarra (CCUN), IdiSNA, Pamplona, Spain.ORCID http://orcid.org/0000-0002-7983-2875
Carmen Rodriguez-ResComputational Biology Program CIMA-Universidad de Navarra, Cancer Center Clínica Universidad de Navarra (CCUN), IdISNA, Pamplona, Spain.
Sofia Huerga-DominguezHematology and Cell Therapy Service, Cancer Center Clínica Universidad de Navarra (CCUN), IdISNA, Pamplona, Spain.
Marina AinciburuHematology-Oncology Program, CIMA, Cancer Center Clínica Universidad de Navarra (CCUN), IdiSNA, Pamplona, Spain.ORCID http://orcid.org/0000-0001-6483-1901
Amaia Vilas-ZornozaHematology-Oncology Program, CIMA, Cancer Center Clínica Universidad de Navarra (CCUN), IdiSNA, Pamplona, Spain.
Patxi San Martin-UrizHematology-Oncology Program, CIMA, Cancer Center Clínica Universidad de Navarra (CCUN), IdiSNA, Pamplona, Spain.ORCID http://orcid.org/0000-0003-1483-4279
Paula Aguirre-RuizHematology-Oncology Program, CIMA, Cancer Center Clínica Universidad de Navarra (CCUN), IdiSNA, Pamplona, Spain.
Asier Ullate-AgoteHematology-Oncology Program, CIMA, Cancer Center Clínica Universidad de Navarra (CCUN), IdiSNA, Pamplona, Spain.
Beñat AricetaHematology-Oncology Program, CIMA, Cancer Center Clínica Universidad de Navarra (CCUN), IdiSNA, Pamplona, Spain.ORCID http://orcid.org/0000-0001-8819-402X
Jose-Maria Lamo-EspinosaDepartment of Orthopedics, Clínica Universidad de Navarra, Pamplona, Spain.
Pamela AchaMDS Research Group, Josep Carreras Leukaemia Research Institut, Universitat Autònoma de Barcelona, Barcelona, Spain.
Oriol CalveteMDS Research Group, Josep Carreras Leukaemia Research Institut, Universitat Autònoma de Barcelona, Barcelona, Spain.
Tamara JimenezCentro de Investigación Biomédica en Red de Cáncer, CIBERONC, Madrid, Spain.ORCID http://orcid.org/0000-0001-5894-2023
Antonieta MoleroService of Hematology, Hospital Universitari Vall d'Hebron, Barcelona; Vall d'Hebron Instituto de Oncología (VHIO), Barcelona, Spain.ORCID http://orcid.org/0000-0002-3735-465X
Maria Julia MontoroService of Hematology, Hospital Universitari Vall d'Hebron, Barcelona; Vall d'Hebron Instituto de Oncología (VHIO), Barcelona, Spain.
Maria Díez-CampeloCentro de Investigación Biomédica en Red de Cáncer, CIBERONC, Madrid, Spain.ORCID http://orcid.org/0000-0002-1467-6779
David ValcarcelService of Hematology, Hospital Universitari Vall d'Hebron, Barcelona; Vall d'Hebron Instituto de Oncología (VHIO), Barcelona, Spain.
Francisco SoléMDS Research Group, Josep Carreras Leukaemia Research Institut, Universitat Autònoma de Barcelona, Barcelona, Spain.ORCID http://orcid.org/0000-0002-3251-2161
Ana Alfonso-PierolaCentro de Investigación Biomédica en Red de Cáncer, CIBERONC, Madrid, Spain.ORCID http://orcid.org/0000-0002-2478-5354
Idoia OchoaInstituto de Ciencia de los Datos e Inteligencia Artificial (DATAI), University of Navarra, Pamplona, Spain.ORCID http://orcid.org/0000-0003-1864-7868
Felipe PrósperHematology-Oncology Program, CIMA, Cancer Center Clínica Universidad de Navarra (CCUN), IdiSNA, Pamplona, Spain. fprosper@unav.es.ORCID http://orcid.org/0000-0001-6115-8790
Teresa EzpondaHematology-Oncology Program, CIMA, Cancer Center Clínica Universidad de Navarra (CCUN), IdiSNA, Pamplona, Spain. tezponda@unav.es.ORCID http://orcid.org/0000-0003-3682-7125
Mikel HernaezComputational Biology Program CIMA-Universidad de Navarra, Cancer Center Clínica Universidad de Navarra (CCUN), IdISNA, Pamplona, Spain. mhernaez@unav.es.ORCID http://orcid.org/0000-0003-0443-2305
Funding
Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III) PI19/00726Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III) PI22/01044
Abstract
While myelodysplastic syndromes with del(5q) (del(5q) MDS) comprises a well-defined hematological subgroup, the molecular basis underlying its origin remains unknown. Using single cell RNA-seq (scRNA-seq) on CD34
Indexed as
Antigens, CD34Chromosome DeletionChromosomes, Human, Pair 5Hematopoietic Stem CellsLenalidomideMyelodysplastic SyndromesSingle-Cell AnalysisAgedAged, 80 and overFemaleGene Expression ProfilingGene Regulatory NetworksHematopoiesisHumansMaleMiddle AgedAntigens, CD34Lenalidomide
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.